Sign in Subscribe
Securities law

Soleno Therapeutics Reports Serious Adverse Event Regarding Patient on VYKAT XR

Strategic Insights

— 1 min read

Soleno Therapeutics, a biopharmaceutical company, has filed a Form 8-K with the U.S. Securities and Exchange Commission, reporting a serious adverse event involving a patient who has passed away while taking VYKAT XR. The patient, a 17-year-old male with a history of co-morbidities, died from an apparent pulmonary embolus. Despite the FDA approval of VYKAT XR following a rigorous clinical program, Soleno Therapeutics has emphasized the importance of administering the medication in accordance with its FDA-approved label, which describes anticipated side effects.

Key Takeaways:

  • Soleno Therapeutics, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on September 10, 2025, regarding a serious adverse event involving a patient on VYKAT XR.
  • The patient, a 17-year-old male, died from an apparent pulmonary embolus, despite having co-morbidities, including lymphedema, superficial thrombophlebitis, and obesity (326 lbs.).
  • VYKAT XR has a proven safety and efficacy profile and was approved by the FDA following a rigorous clinical program.
  • Soleno Therapeutics is committed to reporting all adverse events experienced by individuals who have taken VYKAT XR in accordance with applicable law.
  • The FDA's website clarifies that the existence of a report in the FAERS database does not establish causation and that submission of a report does not mean that the information included in it has been medically confirmed.
  • Soleno Therapeutics will not specifically comment on adverse event cases (including deaths) unless directly related to VYKAT XR use and unexpected per the U.S. Prescribing Information.

Statistics:

  • The patient's age was 17 years.
  • The patient had a history of co-morbidities, including lymphedema, superficial thrombophlebitis, and obesity (326 lbs.).
  • The mean age of death reported from a 40-year mortality study in the U.S. was 29.5 +- 15 years (range: 2 months--67 years).
  • 326 lbs. is the patient's weight at the time of death.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 Form 8-K CURRENT REPORT (September 10, 2025)
  • FDA, FAERS database (as cited in the Form 8-K filing)
  • SOLENO THERAPEUTICS, INC. website and social media channels (cited in the Form 8-K filing)
  • Medical literature and studies on Prader Willi Syndrome and VYKAT XR (cited in the Form 8-K filing)

Read more